ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE-LEUKEMIA - IGCI EXPERIENCE

From October 1984 to December 1994, 142 patients from six IGCI-BMT cen ters (78 acute myelogenous leukemia and 64 acute lymphoblastic leukemi a) received allogeneic bone marrow from their HLA-identical sibling. T he probability of LFS at 60 months is 41% for AML patients and 39% for ALL patients. A better LFS was documented in patients allografted in first CR compared to the patients treated in advanced stage of the dis ease. The overall relapse rate is 27% for AML patients and 45% for ALL patients. The relapse rate is higher for patients allografted in adva nced stage of the disease (47 vs 26% at 60 months for AML and 55 vs 38 % at 60 months for ALL). The incidence of moderate to severe acute GVH D is between 45-50% for both AML and ALL patients. Chronic GVHD was do cumented in 30% of AML patients and 38% of ALL patients. Transplant-re lated mortality for both AML and ALL is about 25%. Relapse and GVHD wi th or without infection are the main causes of death. These results co nfirmed that allogeneic BMT is very effective therapy for patients wit h acute leukemia, especially for patients transplanted in first CR.